Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function.

@article{Dixon2002TherapeuticEO,
  title={Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function.},
  author={Helen Dixon and Chris J. Norbury},
  journal={Cell cycle},
  year={2002},
  volume={1 6},
  pages={362-8}
}
Cytotoxic agents form the basis of most cancer therapies. These agents primarily affect rapidly proliferating cells, so their use incurs morbidity associated with damage to tissues such as bone marrow and gastrointestinal mucosa. Clinical outcome would be improved if it were possible to develop therapeutics with more specific activity against p53-deficient cancers, which account for over 50% of all cases. p53 deficiency alters the cellular response to DNA damage in that it leaves cells with… CONTINUE READING
26 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…